Inflammatory cytokine modulation

"Inflammatory cytokine modulation" does not refer to a single molecule or receptor but rather describes the *therapeutic strategy* or *biological process* by which the activity and balance of pro-inflammatory and anti-inflammatory cytokines are altered. Cytokines are small secreted proteins that serve as key modulators in inflammation and immunity. They include interleukins, interferons, tumor necrosis factors, chemokines, colony-stimulating factors, and transforming growth factors. Pro-inflammatory examples are IL‑1β, IL‑6, TNF-alpha; anti-inflammatory examples are IL‑10 and TGF-beta.\n\nCytokine signaling occurs through binding specific cell-surface receptors—such as those for interleukins or TNF—which then activate intracellular pathways like JAK/STAT and NF-kB that regulate gene expression related to immune responses.[2][4] Dysregulation can lead to chronic inflammation implicated in autoimmune diseases,[5] cancer,[3] cardiovascular disorders,[4] infections,[5] neurodegeneration,[4] among others.\n\nTherapies aimed at "modulating inflammatory cytokines" use biologics like monoclonal antibodies against individual pro-inflammatory mediators or small-molecule inhibitors targeting downstream signaling components.[2][4] Monitoring involves measuring circulating levels of relevant biomarkers such as CRP or individual interleukins.[3]\n\nBecause this term refers broadly to an approach rather than an individual molecular entity—and encompasses multiple targets—it is not considered a canonical drug target itself.

Other names

Cytokine modulationModulation of inflammatory cytokinesCytokine signaling modulationPro-inflammatory cytokine regulationAnti-inflammatory cytokine regulation

Drugs targeting this pathway may: Block pro-inflammatory cytokines or their receptors directly; Inhibit intracellular signaling pathways such as JAK/STAT, NF-kB, MAPK; Enhance anti-inflammatory signals/cytokines.